[go: up one dir, main page]

MX2017016199A - Formulacion de anticuerpo anti-cgrp. - Google Patents

Formulacion de anticuerpo anti-cgrp.

Info

Publication number
MX2017016199A
MX2017016199A MX2017016199A MX2017016199A MX2017016199A MX 2017016199 A MX2017016199 A MX 2017016199A MX 2017016199 A MX2017016199 A MX 2017016199A MX 2017016199 A MX2017016199 A MX 2017016199A MX 2017016199 A MX2017016199 A MX 2017016199A
Authority
MX
Mexico
Prior art keywords
headaches
antibody formulation
cgrp antibody
clusters
episodic
Prior art date
Application number
MX2017016199A
Other languages
English (en)
Other versions
MX395147B (es
Inventor
N Sharma Anant
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2017016199A publication Critical patent/MX2017016199A/es
Publication of MX395147B publication Critical patent/MX395147B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas para anticuerpos anti-CGRP y métodos para usar los mismos, los cuales son útiles para el tratamiento para migrañas, cefaleas episódicas, cefaleas crónicas, cefaleas en racimos crónicas y cefaleas en racimos episódicos.
MX2017016199A 2015-06-17 2016-06-08 Formulación de anticuerpo anti-cgrp. MX395147B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180905P 2015-06-17 2015-06-17
PCT/US2016/036407 WO2016205037A1 (en) 2015-06-17 2016-06-08 Anti-cgrp antibody formulation

Publications (2)

Publication Number Publication Date
MX2017016199A true MX2017016199A (es) 2018-03-01
MX395147B MX395147B (es) 2025-03-24

Family

ID=56131672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016199A MX395147B (es) 2015-06-17 2016-06-08 Formulación de anticuerpo anti-cgrp.

Country Status (31)

Country Link
US (3) US11498959B2 (es)
EP (2) EP4470557A3 (es)
JP (1) JP6438599B2 (es)
KR (1) KR102000867B1 (es)
CN (3) CN118356393A (es)
AR (2) AR104847A1 (es)
AU (1) AU2016280555B2 (es)
BR (1) BR112017023374A2 (es)
CA (1) CA2984185A1 (es)
DK (1) DK3310809T3 (es)
EA (1) EA037580B1 (es)
ES (1) ES3000607T3 (es)
FI (1) FI3310809T3 (es)
HR (1) HRP20241660T1 (es)
HU (1) HUE069368T2 (es)
IL (2) IL292562A (es)
JO (1) JO3772B1 (es)
LT (1) LT3310809T (es)
MA (1) MA49726B1 (es)
MD (1) MD3310809T2 (es)
MX (1) MX395147B (es)
MY (1) MY184266A (es)
NZ (1) NZ737046A (es)
PL (1) PL3310809T3 (es)
PT (1) PT3310809T (es)
RS (1) RS66243B1 (es)
SI (1) SI3310809T1 (es)
TW (1) TWI725973B (es)
UA (1) UA120881C2 (es)
WO (1) WO2016205037A1 (es)
ZA (1) ZA201707324B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2018055573A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
EP3774881A1 (en) * 2018-04-02 2021-02-17 Amgen Inc. Erenumab compositions and uses thereof
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
CN113164683B (zh) * 2018-09-20 2023-04-21 梯瓦制药国际有限责任公司 自动注射器和用于老化的预填充针筒的注射弹簧
BR112020018192A2 (pt) 2019-01-08 2021-08-24 H. Lundbeck A/S Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp
SG11202110637RA (en) * 2019-05-02 2021-10-28 H Lundbeck As Treatment of headache using anti-cgrp antibodies
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100303872B1 (ko) 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
CN1292655C (zh) * 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
EP1592440A4 (en) 2003-02-10 2007-07-11 Elan Pharm Inc IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME
RU2007124933A (ru) * 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PT2620450T (pt) 2005-03-08 2018-12-17 Pfizer Prod Inc Composições de anticorpos anti-ctla-4
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CN101309704B (zh) * 2005-11-14 2012-10-10 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
AU2007331712A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
CL2008000058A1 (es) * 2007-01-09 2008-05-23 Wyeth Corp Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
CN101668540A (zh) * 2007-03-22 2010-03-10 英克隆有限责任公司 稳定的抗体制剂
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
CA2684323A1 (en) * 2007-04-18 2008-10-30 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
SI2331090T1 (en) * 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
CA2743469C (en) * 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
KR20110096553A (ko) * 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
PT2608805T (pt) * 2010-08-23 2017-09-11 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
SI2691112T1 (en) * 2011-03-31 2018-07-31 Merck Sharp & Dohme Corp. STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
CN103748111B (zh) * 2011-05-20 2018-04-27 奥尔德生物控股有限责任公司 抗cgrp组合物及其用途
KR20140084253A (ko) 2011-10-24 2014-07-04 애브비 인코포레이티드 Ｔｎｆ에 대한 면역결합제
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
KR20150110659A (ko) * 2013-01-24 2015-10-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tnf-알파 항원-결합 단백질
MX378344B (es) * 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CN108135983A (zh) * 2015-10-30 2018-06-08 伊莱利利公司 抗cgrp /抗il-23双特异性抗体及其用途

Also Published As

Publication number Publication date
MX395147B (es) 2025-03-24
MA49726A (fr) 2020-06-10
MD3310809T2 (ro) 2025-03-31
AU2016280555A1 (en) 2017-11-16
AR133453A2 (es) 2025-10-01
EP3310809A1 (en) 2018-04-25
IL292562A (en) 2022-06-01
JP2018517727A (ja) 2018-07-05
KR102000867B1 (ko) 2019-07-16
MA49726B1 (fr) 2025-02-28
JP6438599B2 (ja) 2018-12-19
TW201711697A (zh) 2017-04-01
CN118356393A (zh) 2024-07-19
EP4470557A3 (en) 2025-02-26
UA120881C2 (uk) 2020-02-25
NZ737046A (en) 2019-09-27
EP3310809B1 (en) 2024-10-16
MY184266A (en) 2021-03-30
RS66243B1 (sr) 2024-12-31
TWI725973B (zh) 2021-05-01
US20180134772A1 (en) 2018-05-17
DK3310809T3 (da) 2024-12-02
EA201792359A1 (ru) 2018-05-31
HUE069368T2 (hu) 2025-02-28
AR104847A1 (es) 2017-08-16
US20220112277A1 (en) 2022-04-14
ES3000607T3 (en) 2025-03-03
HRP20241660T1 (hr) 2025-02-14
WO2016205037A1 (en) 2016-12-22
SI3310809T1 (sl) 2025-03-31
LT3310809T (lt) 2025-01-10
CA2984185A1 (en) 2016-12-22
EP4470557A2 (en) 2024-12-04
IL255443A0 (en) 2017-12-31
KR20180002858A (ko) 2018-01-08
IL255443B (en) 2022-06-01
FI3310809T3 (fi) 2024-12-07
BR112017023374A2 (pt) 2018-07-24
US20230159628A1 (en) 2023-05-25
JO3772B1 (ar) 2021-01-31
EA037580B1 (ru) 2021-04-16
CN107787229A (zh) 2018-03-09
CN114948847A (zh) 2022-08-30
AU2016280555B2 (en) 2018-11-15
US11498959B2 (en) 2022-11-15
ZA201707324B (en) 2020-01-29
PL3310809T3 (pl) 2025-01-27
HK1245813A1 (en) 2018-08-31
PT3310809T (pt) 2024-12-16

Similar Documents

Publication Publication Date Title
MX2017016199A (es) Formulacion de anticuerpo anti-cgrp.
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
BR112019012342A2 (pt) anticorpos il-11
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
BR112019012343A2 (pt) anticorpos il-11ra
CO2017003005A2 (es) Anticuerpos anti-mfi2
GEAP202114450A (en) Anti-tigit antibodies
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
DK3594238T3 (da) Antistofsammensætninger til tumorbehandling
EA201691974A1 (ru) Антитела против ox40 и способы их применения
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
IL262286A (en) Novel immunogenic cd1d binding peptides
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
MX2017007338A (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis.
BR112017008097A2 (pt) método para tratar condições oculares
BR112016019389A8 (pt) Vacina, e, peptídeo
CR20160444A (es) Proteínas de fusión uti
MX2017005807A (es) Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.
MX2019007433A (es) Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.
BR112016007816A2 (pt) composições peptídicas inovadoras